Hypha’s PolyCYPs® enzymes have been developed to provide an easy-to-use in-vitro catalytic system for the rapid oxidation of organic molecules. PolyCYPs® are formatted into screening kits which allow the convenient and cost effective in-house testing of drug compounds for scalable synthesis of CYP-derived metabolites and hydroxylated derivatives.

New to the market, PolyCYPs® enzymes are mined from Hypha’s talented microbial biotransformation platform and capable of oxidising a wide range of substrate compounds, especially arylic/benzylic -CH, -CH2, -CH3, -tert-butyl, and iso-propyl moieties, as well as aromatic systems for phenols and epoxides. De-alkylation of N- and O-alkyl moieties is also observed. Reactions are scalable either by resupply of the enzymes for production in-house, or for larger scale, production / purification at Hypha.

Enzymes in Hypha’s hydroxylation kit have been rigorously tested for biocatalytic ability against a diverse panel of substrates. So far 84% of substrates tested have been biotransformed to at least one metabolite.